🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Methylene Blue Treatment of Chronic Hepatitis B Virus Infection

RecruitingPhase 2Ages 18 Years - 79 YearsAllFondazione Epatocentro Ticino
NCT06887036 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

HBV infection is a global public health problem. It is estimated that there are more than 250 million HBV carriers worldwide, of whom approximately 600,000 die each year from HBV-related liver disease. Diagnosis and treatment depend on the stage of infection, the degree of liver inflammation, and the progression of fibrosis. Patients with HBeAg-positive or -negative hepatitis are usually treated with nucleos(-t)ide analogues. This treatment inhibits HBV reverse transcriptase and reduces viral replication, but does not affect HBsAg production. Treatment must be continued for life in most cases and is associated with high cumulative costs and the risk of development of resistance. Recently, it has been shown that patients who show a decrease in their HBsAg levels are more likely to become HBsAg negative, seroconvert and be able to stop antiviral treatment, which is the ultimate goal of tr

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Signed informed consent * Age ≥ 18 and \< 80 years * Microbiologically confirmed chronic Hepatitis B Virus infection (according to the old terminology "inactive HBV carrier") * HBsAg levels within 20-15'000 IU/ml measured at the at least twice at 6-18 months apart * HBV DNA PCR levels within 1'000-20'000 IU/ml measured at least twice at 6-18 months apart * Negative pregnancy test in women of child-bearing age Exclusion Criteria: * Documented refusal to participate in the study * Known G-6-Phophatase deficiency * Treatment with a serotoninergic drug * Ongoing treatment with a nucleos(-t)ide treatment * Clinically relevant concomitant liver disease * GPT \> 2xULN * Fibroscan of \> 8.0 KPa obtained ≤ 12 months before Visit 0/Screening * HBeAg positivity * Anti HDV antibody positivity * Breastfeeding women
💊

What it tests

  • Methylene Blue
📍

Where

1 site
Epatocentro Ticino
Lugano, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy